Access For Life
Subcutaneous Implanted Device for Vascular Access
Company Overview
Snapshot
Founded in September 2013 by Roger Mason, Access For Life operates with 1–10 employees. The company has secured funding across two rounds from one disclosed investor, Pharmes Innovations Limited, and also received a grant from EU Horizon 2020.
Business overview
Access For Life develops medical devices designed to facilitate repetitive therapies requiring vascular access for patients with chronic diseases. Its core product, the patented JEM device, is a smart needle guide that attaches to an arterio-venous (AV) fistula or graft and is implanted subcutaneously. This device aims to preserve vessel walls, reduce clinical complications such as perforations and infections, and enable safer, easier repetitive vascular access for treatments like hemodialysis and chemotherapy. The company also integrates sensors into its device to provide clinical data for big data analysis, serving the healthcare providers and patient markets within the Health Tech & Life Sciences sector.
Log in to access full profile ›Company Intelligence Q&A
- What is Access For Life's primary product?
- Access For Life's primary product is the JEM device, a patented subcutaneous implanted device designed to provide safer and easier repetitive vascular access for patients undergoing treatments like hemodialysis and chemotherapy.
- When was Access For Life founded?
- Access For Life was founded in September 2013.
- Who is a founder of Access For Life?
- Roger Mason is a founder of Access For Life.
- Which investor participated in Access For Life's funding round?
- In January 2016, Pharmes Innovations Limited participated in a funding round for Access For Life.
- Did Access For Life receive any grants?
- Yes, in April 2016, Access For Life received a grant from EU Horizon 2020.